View in EDS HTML Full Text PDF Full Text

Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China.

Saved in:
Bibliographic Details
Title: Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China.
Authors: Zhang, Mingjie1 (AUTHOR), Guo, Aihong2 (AUTHOR), Wu, Jin3 (AUTHOR), Wang, Hebo4 (AUTHOR), Zhang, Yongbo5 (AUTHOR), Dong, Hongjuan6 (AUTHOR), Liu, Jianguang7 (AUTHOR), Zhang, Bei8 (AUTHOR), Guo, Huailian9 (AUTHOR), Yu, Tingmin10 (AUTHOR), Lu, Zhihong11 (AUTHOR), Ma, Liheng11 (AUTHOR), Fountaine, Robert J.12 (AUTHOR), Pixton, Glenn C.12 (AUTHOR), Zhong, Qi11 (AUTHOR), Han, Xiaoran11 (AUTHOR), Yu, Shengyuan1 (AUTHOR) yusy1963@126.com
Source: Cephalalgia. Oct2025, Vol. 45 Issue 10, p1-13. 13p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:03331024
DOI:10.1177/03331024251371686